AMENDMENT NO. 1 to the RESEARCH FUNDING AGREEMENT by and between Affimed Therapeutics AG and The Leukemia & Lymphoma SocietyResearch Funding Agreement • June 27th, 2014 • Affimed Therapeutics B.V. • Pharmaceutical preparations
Contract Type FiledJune 27th, 2014 Company IndustryThis Amendment (the “Amendment”) is made as of April 29th, 2014 (the “Amendment Effective Date”), by and between The Leukemia and Lymphoma Society, a New York nonprofit corporation with its principal place of business at 1311 Mamaroneck Avenue, White Plains, New York 10605, United States of America (“LLS”) and Affimed Therapeutics AG, a German limited liability company with its principal place of business at Im Neuenheimer Feld 582, 69120 Heidelberg, Germany (“Affimed”). LLS and Affimed are hereinafter referred to individually as the “Party” and together as the “Parties”.
AMENDMENT NO. 1 to the RESEARCH FUNDING AGREEMENT by and between Affimed Therapeutics AG and The Leukemia & Lymphoma SocietyResearch Funding Agreement • May 23rd, 2014 • Affimed Therapeutics B.V. • Pharmaceutical preparations
Contract Type FiledMay 23rd, 2014 Company IndustryThis Amendment (the “Amendment”) is made as of April 29th, 2014 (the “Amendment Effective Date”), by and between The Leukemia and Lymphoma Society, a New York nonprofit corporation with its principal place of business at 1311 Mamaroneck Avenue, White Plains, New York 10605, United States of America (“LLS”) and Affimed Therapeutics AG, a German limited liability company with its principal place of business at Im Neuenheimer Feld 582, 69120 Heidelberg, Germany (“Affimed”). LLS and Affimed are hereinafter referred to individually as the “Party” and together as the “Parties”.